Glycoconjugates

Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)
DrugDrug NameDrug Indication
DB00012Darbepoetin alfaFor the treatment of anemia (from renal transplants or certain HIV treatment)
DB00016ErythropoietinIndicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
DB00019PegfilgrastimPegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.
DB00020SargramostimFor the treatment of cancer and bone marrow transplant
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB00058Alpha-1-proteinase inhibitorFor chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
DB00099FilgrastimThis drug is a leucocyte growth factor [FDA label] indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [FDA label]. Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia (AML) [FDA label] Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) [FDA label] Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [FDA label] Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [FDA label]. Neupogen is approved for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident [L3739].
DB00290BleomycinFor palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
DB00512VancomycinA variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [FDA Label]. Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196].
DB01584ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
DB01991Tu-514Not Available
DB02557PhosphoramidonNot Available
DB04111BalhimycinNot Available
DB04911OritavancinIndicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
DB04933EritoranInvestigated for use/treatment in sepsis and septicemia.
DB05006AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05446LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB05735CefilavancinInvestigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.
DB05777Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05931PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
DB06149TeicoplaninFor the treatment of bacterial infections caused by susceptible microorganisms.
DB06219DalbavancinDalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. Dalbavancin is not active against gram-negative bacteria; therefore, combination therapy may be clinically indicated if the ABSSSI is polymicrobial and includes a suspected or documented gram-negative pathogen [F2356]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin and other antibacterial drugs, dalbavancin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label, F2356]. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy [FDA Label, F2356]. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy [FDA Label, F2356].
DB06404Human C1-esterase inhibitorFor routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
DB06447E5531Investigated for use/treatment in sepsis and septicemia.
DB06534ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
DB06584TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB09349Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to oral iron therapy.
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB11624Epoetin deltaNot Available
DB12038UlinastatinNot Available
DB12232KRN-7000Not Available
DB12351SiagosideNot Available
DB12431MuplestimNot Available
DB12525MolgramostimNot Available
DB12568TecemotideNot Available
DB12699BalugrastimNot Available
DB12992Bleomycin A6Not Available
DB13144LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
DB13149Protein S humanFor use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.
DB13200LipegfilgrastimIndicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441].
DB13257Ferrous sulfate anhydrousFor the prevention and treatment of iron deficiency anemia [L2252].
DB13299SulglicotideNot Available
DB13615MifamurtideIndicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy [L1203].
DB14111Ceramide NPNot Available
DB14705Ceramide APNot Available
DB14706Ceramide NGNot Available
DB12778RivipanselNot Available
DB05386RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
DB14852PRM-151Not Available
DB15015Recombinant CD40-ligandNot Available
DB15095LeridistimNot Available
DB15150FibronectinNot Available
DB15228AvidinNot Available
DrugDrug NameTargetType
DB00012Darbepoetin alfaErythropoietin receptortarget
DB00016ErythropoietinErythropoietin receptortarget
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget
DB00020SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB00020SargramostimBone marrow proteoglycantarget
DB00020SargramostimInterleukin-3 receptor subunit alphatarget
DB00020SargramostimCytokine receptor common subunit betatarget
DB00020SargramostimSyndecan-2target
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB00058Alpha-1-proteinase inhibitorNeutrophil elastasetarget
DB00099FilgrastimGranulocyte colony-stimulating factor receptortarget
DB00099FilgrastimNeutrophil elastasetarget
DB00290BleomycinDNA ligase 3target
DB00290BleomycinDNA ligase 1target
DB00290BleomycinDNAtarget
DB00290BleomycinBleomycin hydrolaseenzyme
DB00512VancomycinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DB00512VancomycinSerum albumincarrier
DB00512Vancomycinalpha1-acid glycoproteincarrier
DB00512VancomycinHistamine H1 receptorcarrier
DB01991Tu-514UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylasetarget
DB02557PhosphoramidonNeprilysintarget
DB02557PhosphoramidonKell blood group glycoproteintarget
DB04911OritavancinCytochrome P450 3A4enzyme
DB04911OritavancinCytochrome P450 2D6enzyme
DB04911OritavancinCytochrome P450 2C9enzyme
DB04911OritavancinCytochrome P450 2C19enzyme
DB04933EritoranToll-like receptor 4target
DB05332RomiplostimThrombopoietin receptortarget
DB05446LJP 1082Beta-2-glycoprotein 1target
DB05777Thrombomodulin AlfaCoagulation factor Vtarget
DB05777Thrombomodulin AlfaProthrombintarget
DB05793PRO-542Free fatty acid receptor 4target
DB05931PegdinetanibVascular endothelial growth factor receptor 2target
DB06149TeicoplaninD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DB06219DalbavancinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DB06404Human C1-esterase inhibitorComplement C1r subcomponenttarget
DB06404Human C1-esterase inhibitorComplement C1s subcomponenttarget
DB06404Human C1-esterase inhibitorPlasma kallikreintarget
DB06404Human C1-esterase inhibitorCoagulation factor XIItarget
DB06404Human C1-esterase inhibitorProthrombintarget
DB06404Human C1-esterase inhibitorCoagulation factor XItarget
DB06404Human C1-esterase inhibitorTissue-type plasminogen activatortarget
DB06447E5531Toll-like receptor 4target
DB06534ThrombopoietinThrombopoietin receptortarget
DB06584TG4010Mucin-1target
DB06584TG4010Interleukin-2target
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB13144LenograstimGranulocyte colony-stimulating factor receptortarget
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget
DB13200LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB13257Ferrous sulfate anhydrousSerotransferrintransporter
DB13257Ferrous sulfate anhydrousFerritin light chaintransporter
DB13257Ferrous sulfate anhydrousFerritin heavy chaintransporter
DB13257Ferrous sulfate anhydrousDivalent metal ion transporter 1transporter
DB13257Ferrous sulfate anhydrousIron binding protein FbpAtransporter
DB13257Ferrous sulfate anhydrousNADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialenzyme
DB13257Ferrous sulfate anhydrousSuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialenzyme
DB13257Ferrous sulfate anhydrousXanthine dehydrogenase/oxidaseenzyme
DB13257Ferrous sulfate anhydrousAconitate hydratase, mitochondrialenzyme
DB13257Ferrous sulfate anhydrousCytochrome P450 4A11enzyme
DB13257Ferrous sulfate anhydrousSulfite oxidase, mitochondrialenzyme
DB13257Ferrous sulfate anhydrousMyeloperoxidaseenzyme
DB13257Ferrous sulfate anhydrousCatalaseenzyme
DB13257Ferrous sulfate anhydrousNitric oxide synthase, inducibleenzyme
DB13257Ferrous sulfate anhydrousProstaglandin G/H synthase 1enzyme
DB13257Ferrous sulfate anhydrousProstaglandin G/H synthase 2enzyme
DB13257Ferrous sulfate anhydrousTryptophan 5-hydroxylase 1enzyme
DB13257Ferrous sulfate anhydrousProlyl 4-hydroxylase subunit alpha-1enzyme
DB13257Ferrous sulfate anhydrousRibonucleoside-diphosphate reductase large subunitenzyme
DB13257Ferrous sulfate anhydrousPterin-4-alpha-carbinolamine dehydrataseenzyme
DB13257Ferrous sulfate anhydrousTrimethyllysine dioxygenase, mitochondrialenzyme
DB13257Ferrous sulfate anhydrousCeruloplasminenzyme
DB13257Ferrous sulfate anhydrousFree radicalstarget
DB13615MifamurtideToll-like receptor 4target
DB13615MifamurtideNucleotide-binding oligomerization domain-containing protein 2target
DB05386RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB05386RegramostimGM-CSF receptor alpha subunittarget
DB05386RegramostimCholinesteraseenzyme